Suppr超能文献

脑脊液生物标志物和储备变量作为阿尔茨海默病未来“非认知”结局的预测指标

Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease.

作者信息

Ingber Adam P, Hassenstab Jason, Fagan Anne M, Benzinger Tammie L S, Grant Elizabeth A, Holtzman David M, Morris John C, Roe Catherine M

机构信息

Department of Biological Statistics and Computational Biology, Cornell University, Ithaca, NY, USA.

Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.

出版信息

J Alzheimers Dis. 2016;52(3):1055-64. doi: 10.3233/JAD-150478.

Abstract

BACKGROUND

The influence of reserve variables and Alzheimer's disease (AD) biomarkers on cognitive test performance has been fairly well-characterized. However, less is known about the influence of these factors on "non-cognitive" outcomes, including functional abilities and mood.

OBJECTIVE

We examined whether cognitive and brain reserve variables mediate how AD biomarker levels in cognitively normal persons predict future changes in function, mood, and neuropsychiatric behavior.

METHODS

Non-cognitive outcomes were examined in 328 individuals 50 years and older enrolled in ongoing studies of aging and dementia at the Knight Alzheimer Disease Research Center (ADRC). All participants were cognitively normal at baseline (Clinical Dementia Rating [CDR] 0), completed cerebrospinal fluid (CSF) and structural neuroimaging studies within one year of baseline, and were followed for an average of 4.6 annual visits. Linear mixed effects models explored how cognitive reserve and brain reserve variables mediate the relationships between AD biomarker levels and changes in function, mood, and neuropsychiatric behavior in cognitively normal participants.

RESULTS

Education levels did not have a significant effect on predicting non-cognitive decline. However, participants with smaller brain volumes exhibited the worst outcomes on measures of mood, functional abilities, and behavioral disturbance. This effect was most pronounced in individuals who also had abnormal CSF biomarkers.

CONCLUSIONS

The findings suggest that brain reserve plays a stronger, or earlier, role than cognitive reserve in protecting against non-cognitive impairment in AD.

摘要

背景

储备变量和阿尔茨海默病(AD)生物标志物对认知测试表现的影响已得到较为充分的描述。然而,对于这些因素对“非认知”结果(包括功能能力和情绪)的影响,人们了解较少。

目的

我们研究了认知和脑储备变量是否介导认知正常人群中AD生物标志物水平如何预测功能、情绪和神经精神行为的未来变化。

方法

在奈特阿尔茨海默病研究中心(ADRC)正在进行的衰老与痴呆研究中,对328名50岁及以上的个体进行了非认知结果的检查。所有参与者在基线时认知正常(临床痴呆评定量表[CDR]为0),在基线后一年内完成了脑脊液(CSF)和结构性神经影像学研究,并平均随访了4.6次年度访视。线性混合效应模型探讨了认知储备和脑储备变量如何介导认知正常参与者中AD生物标志物水平与功能、情绪和神经精神行为变化之间的关系。

结果

教育水平对预测非认知衰退没有显著影响。然而,脑容量较小的参与者在情绪、功能能力和行为障碍测量中表现出最差的结果。这种效应在脑脊液生物标志物也异常的个体中最为明显。

结论

研究结果表明,在预防AD的非认知损害方面,脑储备比认知储备发挥着更强或更早的作用。

相似文献

2
Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels.
Am J Geriatr Psychiatry. 2016 Nov;24(11):1095-1104. doi: 10.1016/j.jagp.2016.04.004. Epub 2016 Apr 19.
3
Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
J Alzheimers Dis. 2017;60(4):1451-1459. doi: 10.3233/JAD-170511.
5
Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease.
JAMA Neurol. 2015 Jun;72(6):699-706. doi: 10.1001/jamaneurol.2015.0098.
7
Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
JAMA Neurol. 2015 Sep;72(9):1029-42. doi: 10.1001/jamaneurol.2015.1285.
8
Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
JAMA Neurol. 2015 Jun;72(6):656-65. doi: 10.1001/jamaneurol.2015.0202.
9
Tau and amyloid biomarkers modify the degree to which cognitive reserve and brain reserve predict cognitive decline.
J Int Neuropsychol Soc. 2023 Jul;29(6):572-581. doi: 10.1017/S1355617722000546. Epub 2022 Aug 30.
10
Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition.
Brain. 2011 May;134(Pt 5):1479-92. doi: 10.1093/brain/awr049. Epub 2011 Apr 7.

引用本文的文献

1
Association between educational attainment and amyloid deposition across the spectrum from normal cognition to dementia: A meta-analysis.
IBRO Neurosci Rep. 2025 Jun 12;19:133-142. doi: 10.1016/j.ibneur.2025.05.010. eCollection 2025 Dec.
3
Interaction between Cognitive Reserve and Biomarkers in Alzheimer Disease.
Int J Mol Sci. 2020 Aug 30;21(17):6279. doi: 10.3390/ijms21176279.
5
How the cognitive reserve interacts with β-amyloid deposition in mitigating FDG metabolism: An observational study.
Medicine (Baltimore). 2017 Apr;96(16):e5876. doi: 10.1097/MD.0000000000005876.

本文引用的文献

2
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.
Sci Transl Med. 2014 Mar 5;6(226):226ra30. doi: 10.1126/scitranslmed.3007901.
3
CSF biomarkers of Alzheimer disease: "noncognitive" outcomes.
Neurology. 2013 Dec 3;81(23):2028-31. doi: 10.1212/01.wnl.0000436940.78152.05. Epub 2013 Nov 8.
4
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease.
Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):E4502-9. doi: 10.1073/pnas.1317918110. Epub 2013 Nov 5.
5
A new algorithm for predicting time to disease endpoints in Alzheimer's disease patients.
J Alzheimers Dis. 2014;38(3):661-8. doi: 10.3233/JAD-131142.
6
Cognitive declines precede and predict functional declines in aging and Alzheimer's disease.
PLoS One. 2013 Sep 2;8(9):e73645. doi: 10.1371/journal.pone.0073645. eCollection 2013.
7
Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
N Engl J Med. 2012 Aug 30;367(9):795-804. doi: 10.1056/NEJMoa1202753. Epub 2012 Jul 11.
8
Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.
Ann Neurol. 2011 Aug;70(2):274-85. doi: 10.1002/ana.22448.
10
Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease.
Neurology. 2011 Feb 8;76(6):501-10. doi: 10.1212/WNL.0b013e31820af900. Epub 2011 Jan 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验